Physician profile
Pavel Greg Buzadzhi
NPI 1790318426
$26,109.21
in general payments reported to CMS, 2019-2025
30 companies · $9,123 in 2025
The $9,123 reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,833 · 2022: $2,211 · 2023: $6,978 · 2024: $5,964 · 2025: $9,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Travel and Lodging: $9,962 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,993.06 |
| Travel and Lodging | $9,961.96 |
| Education | $110.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $8,257.96 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Abiomed | $3,960.64 | 2023-2025 | Impella |
| United Therapeutics Corporation | $2,538.39 | 2021-2025 | Tyvaso, Tyvaso, Orenitram |
| Cvrx, INC. | $2,070.66 | 2023-2025 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $1,337.26 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,062.47 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $1,059.33 | 2022-2025 | Farxiga, Wainua, Brilinta |
| Merck Sharp & Dohme LLC | $1,015.02 | 2022-2025 | Verquvo, Winrevair |
| Alnylam Pharmaceuticals INC. | $993.75 | 2021-2025 | Amvuttra, Onpattro |
| Novartis Pharmaceuticals Corporation | $755.18 | 2021-2025 | |
| Pfizer INC. | $648.02 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $389.81 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.37 | 2021-2025 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $276.18 | 2023-2024 | Inpefa |
| Novo Nordisk INC | $265.91 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $253.35 | 2022-2025 | Camzyos, Eliquis |
| Ancora Heart, INC. | $143.70 | 2023-2025 | Accucinch |
| Janssen Pharmaceuticals, INC | $119.15 | 2021-2023 | Xarelto |
| Akcea Therapeutics, INC. | $106.50 | 2021 | |
| Impulse Dynamics (USA) INC. | $105.30 | 2022-2023 | Optimizer |
| Scpharmaceuticals INC. | $65.36 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $58.67 | 2024 | Assure Wcd |
| Nuwellis, INC. | $55.63 | 2021-2023 | Aquadex Smartflow Console |
| Amgen INC. | $54.93 | 2021 | |
| Daiichi Sankyo INC. | $42.17 | 2023 | Injectafer |
| Arbor Pharmaceuticals, INC. | $40.72 | 2021 | |
| Philips North America LLC | $31.93 | 2022 | |
| Edwards Lifesciences Corporation | $23.73 | 2024 | |
| Irhythm Technologies, INC. | $21.67 | 2022 | |
| Amarin Pharma, INC. | $19.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pavel Buzadzhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.